Genetic risk factors for major bleeding in patients treated with warfarin in a community setting

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 6, 2014, Pages 636-643

  Roth, J A ^a,b   Boudreau, D ^a,b   Fujii, M M ^b   Farin, F M ^a   Rettie, A E ^a   Thummel, K E ^a   Veenstra, D L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CYTOCHROME P 450 F2; CYTOCHROME P450; CYTOCHROME P450 2C9; UNCLASSIFIED DRUG; WARFARIN;

AGED; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BODY MASS; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CHARLSON COMORBIDITY INDEX; COMMUNITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG USE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HUMAN; HYPERTENSION; INTEGRATED HEALTH CARE SYSTEM; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SELF REPORT; TREATMENT DURATION; UNITED STATES;

AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DIET; DRUG INTERACTIONS; ETHNIC GROUPS; FEMALE; GENETIC ASSOCIATION STUDIES; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; RISK FACTORS; SEX CHARACTERISTICS; WARFARIN; WASHINGTON;

EID: 84901234705     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.26     Document Type: Article

References (48)

1. Go, A.S. et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA 290, 2685-2692 (2003
2. Agarwal, S., Hachamovitch, R. & Menon, V. Current trial-Associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: A meta-Analysis. Arch. Intern. Med. 172, 623-31; discussion 631 (2012
3. Salazar, C.A., Malaga, G. & Malasquez, G. Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement. Coch. Database Syst. Rev. 2010(4), CD005981 (2010
4. Haq, S.A., Heitner, J.F., Sacchi, T.J. & Brener, S.J. Long-Term effect of chronic oral anticoagulation with warfarin after acute myocardial infarction. Am. J. Med. 123, 250-258 (2010
5. Gurwitz, J.H. et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289, 1107-1116 (2003
6. Hylek, E.M. & Singer, D.E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann. Intern. Med. 120, 897-902 (1994
7. Fihn, S.D., Callahan, C.M., Martin, D.C., McDonell, M.B., Henikoff, J.G. & White, R.H. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann. Intern. Med. 124, 970-979 (1996
8. Torn, M., Cannegieter, S.C., Bollen, W.L., van der Meer, F.J., van der Wall, E.E. & Rosendaal, F.R. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: A prospective study of 4202 patients. Arch. Intern. Med. 169, 1203-1209 (2009
9. Wysowski, D.K., Nourjah, P. & Swartz, L. Bleeding complications with warfarin use: A prevalent adverse effect resulting in regulatory action. Arch. Intern. Med. 167, 1414-1419 (2007
10. Baczek, V.L., Chen, W.T., Kluger, J. & Coleman, C.I. Predictors of warfarin use in atrial fibrillation in the United States: A systematic review and meta-Analysis. BMC Fam. Pract. 13, 5 (2012
11. Gage, B.F. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331 (2008
12. Limdi, N.A. & Veenstra, D.L. Expectations, validity, and reality in pharmacogenetics. J. Clin. Epidemiol. 63, 960-969 (2010
13. Aithal, G.P., Day, C.P., Kesteven, P.J. & Daly, A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719 (1999
14. Wadelius, M. et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 4, 40-48 (2004
15. Takeuchi, F. et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433 (2009
16. Limdi, N.A. et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9, 1445-1458 (2008
17. Higashi, M.K. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002
18. Margaglione, M. et al. Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84, 775-778 (2000
19. Rieder, M.J. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005
20. Wadelius, M. et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007
21. Wadelius, M. et al. The largest prospective warfarin-Treated cohort supports genetic forecasting. Blood 113, 784-792 (2009
22. Limdi, N.A., Wiener, H., Goldstein, J.A., Acton, R.T. & Beasley, T.M. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol. Dis. 43, 119-128 (2009
23. US Food and Drug Administration. [FDA approves updated warfarin (coumadin) prescribing information. Press release, 16 August 2007
24. McDonald, M.G., Rieder, M.J., Nakano, M., Hsia, C.K. & Rettie, A.E. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol. 75, 1337-1346 (2009
25. Caldwell, M.D. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112 (2008
26. Bejarano-Achache, I., Levy, L., Mlynarsky, L., Bialer, M., Muszkat, M. & Caraco, Y. Effects of CYP4F2 polymorphism on response to warfarin during induction phase: A prospective, open-label, observational cohort study. Clin. Ther. 34, 811-823 (2012
27. Lund, K., Gaffney, D., Spooner, R., Etherington, A.M., Tansey, P. & Tait, R.C. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates. Br. J. Haematol. 158, 256-261 (2012
28. Kirley, K., Qato, D.M., Kornfield, R., Stafford, R.S. & Alexander, G.C. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ. Cardiovasc. Qual. Outcomes 5, 615-621 (2012
29. IMS Institute for Healthcare Informatics. The use of medicines in the United States: Review of 2011, http://www.imshealth.com/ims/Global/Content/ Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII-Medicines-in-U. S-Report-2011.pdf 2012
30. Rodriguez, S., Gaunt, T.R. & Day, I.N. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 169, 505-514 (2009
31. Palareti, G. & Cosmi, B. Bleeding with anticoagulation therapy-who is at risk, and how best to identify such patients. Thromb. Haemost. 102, 268-278 (2009
32. Fang, M.C. et al. A new risk scheme to predict warfarin-Associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J. Am. Coll. Cardiol. 58, 395-401 (2011
33. Saunders, K.W., Davis, R.L., Stergachis A. Pharmacoepidemiology. (Wiley, West Sussex, UK, 2005
34. Arnason, T., Wells, P.S., van Walraven, C. & Forster, A.J. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb. Res. 118, 253-262 (2006
35. White, R.H., Beyth, R.J., Zhou, H. & Romano, P.S. Major bleeding after hospitalization for deep-venous thrombosis. Am. J. Med. 107, 414-424 (1999
36. Cunningham, A., Stein, C.M., Chung, C.P., Daugherty, J.R., Smalley, W.E.& Ray, W.A. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol. Drug Saf. 20, 560-566 (2011
37. Langholz, B., Goldstein, L. Risk set sampling in epidemiologic cohort studies. Statist. Sci. 11(1), 35-53 (1996
38. Garg, R.K. et al. Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy data. Pharmacoepidemiol. Drug Saf. 20, 313-316 (2011
39. Psaty, B.M. et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274, 620-625 (1995
40. Trikalinos, T.A., Salanti, G., Khoury, M.J. & Ioannidis, J.P. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am. J. Epidemiol. 163, 300-309 (2006
41. Limdi, N.A. et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther. 83, 312-321 (2008
42. Mantha, S., Pianka, A.M. & Tsapatsaris, N. Determinants of intracranial hemorrhage incidence in patients on oral anticoagulation followed at the Lahey clinic. J. Thromb. Thrombolysis 32, 334-342 (2011
43. Hylek, E.M., Evans-Molina, C., Shea, C., Henault, L.E. & Regan, S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115, 2689-2696 (2007
44. Palareti, G. et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348, 423-428 (1996
45. Lane, S. et al. The population pharmacokinetics of R-And S-warfarin: Effect of genetic and clinical factors. Br. J. Clin. Pharmacol. 73, 66-76 (2012
46. Lindsey, J.K. & Jones, B. Choosing among generalized linear models applied to medical data. Stat. Med. 17, 59-68 (1998
47. Wagenmakers, E.J. & Farrell, S. AIC model selection using Akaike weights. Psychon. Bull. Rev. 11, 192-196 (2004
48. Apostolakis, S., Lane, D.A., Guo, Y., Buller, H. & Lip, G.Y. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: The AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J. Am. Coll. Cardiol. 60, 861-867 (2012